

3/7/3 (Item 3 from file: 5)
DIALOG(R)File 5: BIOSIS Previews(R)
(c) 1999 BIOSIS. All rts. reserv.

10822331 BIOSIS NO.: 199799443476
A plasmid-based **vaccine** to elicit autoantibodies to **cholesteryl
ester transfer protein** (CETP) for the
prevention/treatment of atherosclerosis.

AUTHOR: Thomas L J; Picard M D; Stewart S E; Waite B C D; Lin A Y;
Rittershaus C W; Pettey C L
AUTHOR ADDRESS: T Cell Sci. Inc., Needham, MA, USA

JOURNAL: Journal of Allergy and Clinical Immunology 99 (1 PART 2):pS187
1997

CONFERENCE/MEETING: Joint Meeting of the American Academy of Allergy,
Asthma and Immunology, the American Association of Immunologists and the
Clinical Immunology Society San Francisco, California, USA February
21-26, 1997

ISSN: 0091-6749

RECORD TYPE: Citation

3/7/6 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 1999 Derwent Publ Ltd. All rts. reserv.

0239180 DBA Accession No.: 99-09281 PATENT

Vaccine against cholesteryl ester transfer

protein - vaccine and nucleic acid vaccine which lowers levels of low-density lipoprotein and cholesterol, useful for prevention and therapy of heart disease and atherosclerosis

AUTHOR: Rittershaus C W; Thomas L J

CORPORATE SOURCE: Needham, MA, USA.

PATENT ASSIGNEE: Avant-Immunotherapeutics 1999

PATENT NUMBER: WO 9920302 PATENT DATE: 990429 WPI ACCESSION NO.: 99-302645 (9925)

PRIORITY APPLIC. NO.: US 954643 APPLIC. DATE: 971020

NATIONAL APPLIC. NO.: WO 98US22145 APPLIC. DATE: 981020

LANGUAGE: English

ABSTRACT: A vaccine is claimed that promotes the production of antibodies specific for endogenous **cholesteryl ester transfer protein (CETP)** in a mammal. The vaccine comprises a non-endogenous, humanized rabbit, mouse or monkey CETP, or an allelic variant of human CETP which may be combined with an adjuvant to produce a non-specific mammalian immune response stimulation. Also new is a nucleic acid vaccine comprising a mammalian cell promoter linked to a sequence encoding a non-endogenous CETP. Antibody binding to endogenous **CETP** following **vaccination** reduces its activity and thus the transfer of cholesterol from high-density lipoprotein to very-low-density lipoprotein. Preferably, the vaccine comprises humanized rabbit **CETP** of 447 amino acids, and the nucleic acid vaccines include a cytomegalo virus promoter. A typical vector for use in the vaccine is plasmid pCMV-CETP-TT (ATCC 98038). The vaccines are used to modulate plasma levels of lipoproteins in order to prevent heart disease and atherosclerotic lesion formation. (61pp)

3/7/7 (Item 2 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 1999 Derwent Publ Ltd. All rts. reserv.

0220003 DBA Accession No.: 98-01600 PATENT

DNA plasmid based vaccine - nucleic acid vaccine for cardiovascular disease

AUTHOR: Thomas L J

CORPORATE SOURCE: Needham, MA, USA.

PATENT ASSIGNEE: T-Cell-Sci. 1997

PATENT NUMBER: WO 9741227 PATENT DATE: 971106 WPI ACCESSION NO.: 97-549731 (9750)

PRIORITY APPLIC. NO.: US 802967 APPLIC. DATE: 970221

NATIONAL APPLIC. NO.: WO 97US7294 APPLIC. DATE: 970501

LANGUAGE: English

ABSTRACT: A new nucleic acid vaccine comprises a DNA sequence (I) encoding an immunogenic protein, where at least 1 segment of (I) encodes a B-lymphocyte epitope of cholesterylester-transferase protein (CETP) linked with at least 1 segment encoding a broad range helper T-lymphocyte epitope, where the nucleotide segment is operably linked to a promoter for directing transcription of (I) in a mammalian cell. Also claimed are: a DNA based plasmid vaccine comprising a nucleotide sequence comprising the immediate early promoter/enhancer region of

cytomegalo virus is probably linked to a structural DNA segment encoding an immunogenic protein selected from preferred regions of a disclosed protein sequence; a DNA plasmid-based vaccine comprising a DNA segment encoding a broad range T-lymphocyte epitope. The nucleic acid vaccine can be used to elevate the ratio of circulating high density lipoproteins to circulating low density lipoproteins, very low density lipoproteins or total cholesterol in a human and for reducing the level of endogenous CETP activity in a human. The vaccine can also be used to induce antibodies and for cardiovascular disease